Health Care & Life Sciences » Biotechnology | VistaGen Therapeutics Inc.

VistaGen Therapeutics Inc. | Income Statement

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
-
-
-
1,250.00
-
91.20
Cost of Goods Sold (COGS) incl. D&A
54.60
59.10
53.50
-
80.70
91.20
Gross Income
54.60
59.10
53.50
-
80.70
91.20
SG&A Expense
4,974.30
6,718.00
17,796.70
11,092.90
13,825.90
24,439.30
EBIT
5,028.90
6,777.10
17,850.20
9,897.80
13,906.60
24,530.50
Unusual Expense
3,566.90
2,422.60
28,594.90
350.70
428.00
48.50
Non Operating Income/Expense
-
135.00
3.70
-
-
-
Interest Expense
1,513.00
4,553.70
776.80
4.60
8.90
8
Pretax Income
2,965.00
13,883.40
47,218.20
10,253.10
14,343.50
24,587
Income Tax
2.70
2.40
2.30
2.40
2.40
2.60
Consolidated Net Income
2,967.70
13,885.80
47,220.50
10,255.50
14,345.90
24,589.60
Net Income
2,967.70
13,885.80
47,220.50
10,255.50
14,345.90
24,589.60
Net Income After Extraordinaries
2,967.70
13,885.80
47,220.50
10,255.50
14,345.90
24,589.60
Net Income Available to Common
2,967.70
13,885.80
51,419.00
11,623.60
15,575.50
25,729.50
EPS (Basic)
3.80
10.61
29.08
1.54
1.12
0.90
Basic Shares Outstanding
1,098.70
1,318.80
1,768.00
7,531.60
13,890.00
28,562.50
EPS (Diluted)
3.81
10.61
29.08
1.54
1.12
0.90
Diluted Shares Outstanding
1,098.70
1,318.80
1,768.00
7,531.60
13,890.00
28,562.50
EBITDA
4,974.30
6,718.00
17,796.70
9,842.90
13,825.90
24,439.30
Non-Operating Interest Income
10.00
5.00
-
-
-
-
Preferred Dividends
-
-
4,198.50
1,368.10
1,229.60
1,139.90

About VistaGen Therapeutics

View Profile
Address
343 Allerton Avenue
South San Francisco California 94080
United States
Employees -
Website http://www.vistagen.com
Updated 07/08/2019
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.